Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06308419 · ClinicalTrials.gov registry record · Phase 1
A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions
A Phase 1 study of Leiomyosarcoma and Soft Tissue Sarcomas, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT06308419 is a Phase 1 study of Leiomyosarcoma and Soft Tissue Sarcomas that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 18 participants, below the 121-participant average among 16 other Leiomyosarcoma trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06308419, a Phase 1 study of Leiomyosarcoma and Soft Tissue Sarcomas, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
To find a recommended dose of gemcitabine and nab-sirolimus that can be given in combination to participants with advanced leiomyosarcomas or soft-tissue sarcomas.
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG Nab-Sirolimus
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2024-08-14 |
| Est. Completion | 2031-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06308419
The ClinicalTrials.gov registry entry for NCT06308419 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 121-participant average among 16 other Leiomyosarcoma trials with a reported enrollment target (85% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Leiomyosarcoma appearing as the primary indexed condition, and to 2 interventions - of which Gemcitabine is the first listed.
NCT06308419 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06308419 about?
NCT06308419 is a clinical study titled "A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions". To find a recommended dose of gemcitabine and nab-sirolimus that can be given in combination to participants with advanced leiomyosarcomas or soft-tissue sarcomas.
What is the current status of trial NCT06308419?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2024-08-14. Estimated completion is 2031-02-01.
What conditions does trial NCT06308419 study?
This clinical trial studies the following conditions: Leiomyosarcoma, Soft Tissue Sarcomas.
What interventions are being tested in trial NCT06308419?
The interventions under investigation include: Gemcitabine (DRUG), Nab-Sirolimus (DRUG).
Who is sponsoring clinical trial NCT06308419?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06308419 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leiomyosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)
COMPLETED · Phase 1
-
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
COMPLETED · Phase 1
-
Localized Leiomyosarcoma Biomarker Protocol
RECRUITING
-
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
RECRUITING · Phase 3
-
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.